期刊
EXPERT OPINION ON DRUG DISCOVERY
卷 7, 期 7, 页码 613-632出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/17460441.2012.687719
关键词
antivirals; arenavirus; Machupo; therapeutics; viral hemorrhagic fever
资金
- Joint Science and Technology Office Transformational Medical Technologies [TMTI0048_09_RDE_T]
- NIAID [HHSN272200200016I]
Introduction: Seven arenaviruses cause viral hemorrhagic fever in humans: the Old World arenaviruses Lassa and Lujo, and the New World Clade B arenaviruses Machupo (MACV), Junin (JUNV), Guanarito (GTOV), Sabia (SABV), and Chapare (CHPV). All of these viruses are Risk Group 4 biosafety pathogens. MACV causes human disease outbreak with high case-fatality rates. To date, at least 1,200 cases with approximate to 200 fatalities have been recorded. Areas covered: This review summarizes available systems and technologies for the identification of antivirals against MACV. Furthermore, the article summarizes animal models that have been used for the in vivo evaluation of novel inhibitors. The article highlights present treatments for arenaviral diseases and provides an overview of efficacious small molecules and other therapeutics reported to date. Finally, the article summarizes strategies to identify novel inhibitors for anti-arenaviral therapy. Expert opinion: New high-throughput approaches to quantitate infection rates of arenaviruses, as well as viruses modified to carry reporter genes, will accelerate compound screens and drug discovery efforts. RNAi, gene expression profiling and proteomics studies will identify host targets for therapeutic intervention. New discoveries in the cell entry mechanism of MACV and other arenaviruses as well as extensive structural studies of arenaviral L and NP could facilitate the rational design of antivirals effective against all pathogenic New World arenaviruses.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据